Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.
作者： Katsuyuki Hotta , Katsuyuki Kiura , Masahiro Tabata , Shingo Harita , Kenichi Gemba
DOI: 10.1097/00130404-200509000-00010
关键词: Lung cancer 、 Pulmonary fibrosis 、 Gefitinib 、 Oncology 、 Confidence interval 、 Acute Interstitial Pneumonia 、 Internal medicine 、 Odds ratio 、 Interstitial lung disease 、 Diffuse alveolar damage 、 Medicine
摘要: UNLABELLED Risk factors for the development of interstitial lung disease in patients with non-small cell cancer receiving gefitinib and prognostic after have not been established. The aim this study was to retrospectively identify evaluate these possible factors. PATIENTS AND METHODS We reviewed clinical records radiographs 365 consecutive who received West Japan between 2000 2003. RESULTS In total, 330 were eligible evaluation, 15 (4.5%) finally confirmed developed by blinded expert review. Multivariate analysis revealed that preexisting pulmonary fibrosis, poor performance status, prior thoracic irradiation independent risk disease, odds ratios 21.0 (95% confidence interval, 5.12-86.3, P < 0.0001), 9.70 (2.27-41.4, = 0.001), 4.33 (1.27-14.8, 0.019), respectively. Among eight died condition. Short interval from initiation treatment onset acute pneumonia pattern, presence pre-existing fibrosis associated prognosis. DISCUSSION Our results suggest importance patient selection based on Japanese population identified.
elsevier.com
sci-hub.se 参考文章(11)
V. Rusch, Ethan Dmitrovsky, C. Cordon-Cardo, S. Hoda, M. Zaman, Jonathan M Kurie, J. Mcintosh, J. Baselga, J. Orazem, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Research. ,vol. 53, pp. 2379- 2385 ,(1993)
Syed H. Abid, Vikas Malhotra, Michael C. Perry, Radiation-induced and chemotherapy-induced pulmonary injury Current Opinion in Oncology. ,vol. 13, pp. 242- 248 ,(2001) , 10.1097/00001622-200107000-00006
Toshimi Takano, Yuichiro Ohe, Masahiko Kusumoto, Ukihide Tateishi, Seiichiro Yamamoto, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Tomohide Tamura, Tetsuro Kodama, Nagahiro Saijo, Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib Lung Cancer. ,vol. 45, pp. 93- 104 ,(2004) , 10.1016/J.LUNGCAN.2004.01.010
M Volm, W Rittgen, P Drings, Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. British Journal of Cancer. ,vol. 77, pp. 663- 669 ,(1998) , 10.1038/BJC.1998.106
Jeffrey E. Michaelson, Samuel M. Aguayo, Jesse Roman, IDIOPATHIC PULMONARY FIBROSIS: A PRACTICAL APPROACH FOR DIAGNOSIS AND MANAGEMENT Chest. ,vol. 118, pp. 788- 794 ,(2000) , 10.1378/CHEST.118.3.788
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, Andrea C. Kay, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial JAMA. ,vol. 290, pp. 2149- 2158 ,(2003) , 10.1001/JAMA.290.16.2149
Akira Inoue, Yasuo Saijo, Makoto Maemondo, Kazunori Gomi, Yutaka Tokue, Yuichiro Kimura, Masahito Ebina, Toshiaki Kikuchi, Takuya Moriya, Toshihiro Nukiwa, Severe acute interstitial pneumonia and gefitinib. The Lancet. ,vol. 361, pp. 137- 139 ,(2003) , 10.1016/S0140-6736(03)12190-3
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga, None, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2237- 2246 ,(2003) , 10.1200/JCO.2003.10.038
J Guillermo Paez, Pasi A Janne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J Eck, William R Sellers, Bruce E Johnson, Matthew Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. ,vol. 304, pp. 1497- 1500 ,(2004) , 10.1126/SCIENCE.1099314
A. B. Miller, B. Hoogstraten, M. Staquet, A. Winkler, Reporting results of cancer treatment Cancer. ,vol. 47, pp. 207- 214 ,(1981) , 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6